Wall St futures flat amid US-China trade jitters; bank earnings in focus
BeOne Medicines Ltd. (NASDAQ:ONC) SVP, General Counsel, Lee Chan Henry, sold 10,671 American Depositary Shares of the company on October 8, 2025, for approximately $3.74 million. The sales were executed in a price range of $347.82 to $351.1232, near the stock’s 52-week high of $355.30. The company’s shares have surged 81.8% year-to-date, according to InvestingPro data.
The transactions were executed under a Rule 10b5-1 trading plan adopted on May 14, 2025.
On the same day, Lee Chan Henry also exercised options to acquire a total of 124,268 American Depositary Shares, for a total value of $2.02 million, at prices ranging from $159.03 to $213.32.
Following these transactions, Lee Chan Henry directly owns 223,106 ordinary shares of BeOne Medicines Ltd., a stake in the $37 billion market cap company. InvestingPro analysis shows the company maintains a GREAT financial health score, with 8 additional key insights available to subscribers.
In other recent news, BeOne Medicines has been the focus of several developments. Barclays initiated coverage on BeOne Medicines with an Overweight rating, setting a price target of $385.00, while Bernstein SocGen Group raised its price target to $362.00 from $259.00, maintaining a Market Perform rating. Citizens JMP reiterated its Market Outperform rating with a price target of $348.00. These updates come as BeOne Medicines announced positive topline results from a Phase 1/2 study of sonrotoclax in patients with relapsed/refractory mantle cell lymphoma, meeting the primary endpoint of overall response rate. The study involved 125 adult patients previously treated with a Bruton’s tyrosine kinase inhibitor and anti-CD20 therapy. Additionally, BeOne’s total estimates for its three B-cell products were increased from $8 billion to $10 billion, with Zanu valued at $5 billion, Sonro at $3 billion, and BGB-16673 at $2 billion. Meanwhile, Oncolytics Biotech has unveiled the design for its registration-directed clinical trial in first-line pancreatic ductal adenocarcinoma, featuring a three-arm design with different treatment combinations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.